{"id":"https://openalex.org/W2139295697","doi":"https://doi.org/10.1200/jco.2005.03.7804","title":"Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy","display_name":"Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy","publication_year":2006,"publication_date":"2006-06-16","ids":{"openalex":"https://openalex.org/W2139295697","doi":"https://doi.org/10.1200/jco.2005.03.7804","mag":"2139295697","pmid":"https://pubmed.ncbi.nlm.nih.gov/16782912"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.03.7804","doi":"https://doi.org/10.1200/jco.2005.03.7804","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.03.7804","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5105370289","display_name":"Matthew R. Smith","orcid":"https://orcid.org/0009-0005-5055-8672","observed_orcids":["https://orcid.org/0009-0005-5055-8672"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew R. Smith","raw_affiliation_strings":["From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I4210087915","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045746656","display_name":"Judith B. Manola","orcid":"https://orcid.org/0000-0001-6486-7998","observed_orcids":["https://orcid.org/0000-0001-6486-7998"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judith Manola","raw_affiliation_strings":["From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I4210087915","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106084072","display_name":"Donald S. Kaufman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donald S. Kaufman","raw_affiliation_strings":["From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I4210087915","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078027978","display_name":"William K. Oh","orcid":"https://orcid.org/0000-0001-5113-8147","observed_orcids":["https://orcid.org/0000-0001-5113-8147"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William K. Oh","raw_affiliation_strings":["From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I4210087915","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043769628","display_name":"Glenn J. Bubley","orcid":"https://orcid.org/0000-0002-3062-643X","observed_orcids":["https://orcid.org/0000-0002-3062-643X"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Glenn J. Bubley","raw_affiliation_strings":["From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I4210087915","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056766924","display_name":"Philip W. Kantoff","orcid":"https://orcid.org/0000-0001-7275-0597","observed_orcids":["https://orcid.org/0000-0001-7275-0597"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip W. Kantoff","raw_affiliation_strings":["From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I4210087915","https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":12.3776,"has_fulltext":false,"cited_by_count":127,"citation_normalized_percentile":{"value":0.98879753,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"24","issue":"18","first_page":"2723","last_page":"2728"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9291999936103821,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9291999936103821,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":0.03400000184774399,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.027499999850988388,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/celecoxib","display_name":"celecoxib","score":1.0},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.7419999837875366},{"id":"https://openalex.org/keywords/cox-2-inhibitors","display_name":"COX-2 inhibitors","score":0.8119999766349792},{"id":"https://openalex.org/keywords/prostate-specific-antigen","display_name":"prostate-specific antigen","score":0.7639999985694885},{"id":"https://openalex.org/keywords/psa-doubling-time","display_name":"PSA doubling time","score":0.9290000200271606},{"id":"https://openalex.org/keywords/psa-velocity","display_name":"PSA velocity","score":0.871999979019165},{"id":"https://openalex.org/keywords/recurrent-prostate-cancer","display_name":"recurrent prostate cancer","score":0.7020000219345093},{"id":"https://openalex.org/keywords/radical-prostatectomy","display_name":"radical prostatectomy","score":0.9829999804496765},{"id":"https://openalex.org/keywords/radiotherapy","display_name":"radiotherapy","score":0.9279999732971191},{"id":"https://openalex.org/keywords/cardiovascular-safety","display_name":"cardiovascular safety","score":0.5630000233650208},{"id":"https://openalex.org/keywords/early-trial-termination","display_name":"early trial termination","score":0.453000009059906}],"concepts":[{"id":"https://openalex.org/C2776467144","wikidata":"https://www.wikidata.org/wiki/Q408801","display_name":"Celecoxib","level":2,"score":0.9509265422821045},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9190855026245117},{"id":"https://openalex.org/C2779466945","wikidata":"https://www.wikidata.org/wiki/Q1765251","display_name":"Prostatectomy","level":4,"score":0.7993143200874329},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7338505983352661},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7139853835105896},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.5765340328216553},{"id":"https://openalex.org/C2776235491","wikidata":"https://www.wikidata.org/wiki/Q9625","display_name":"Prostate","level":3,"score":0.4905218482017517},{"id":"https://openalex.org/C2781406297","wikidata":"https://www.wikidata.org/wiki/Q409450","display_name":"Prostate-specific antigen","level":4,"score":0.47882893681526184},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4313841760158539},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.39075756072998047},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.37719178199768066},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36451637744903564},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.09885179996490479},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068579","descriptor_name":"Celecoxib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011468","descriptor_name":"Prostatectomy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011878","descriptor_name":"Radiotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017430","descriptor_name":"Prostate-Specific Antigen","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D052246","descriptor_name":"Cyclooxygenase 2 Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D052246","descriptor_name":"Cyclooxygenase 2 Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1200/jco.2005.03.7804","doi":"https://doi.org/10.1200/jco.2005.03.7804","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.03.7804","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:16782912","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16782912","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.1009.9798","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.1009.9798","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://www.rima.org/web/medline_pdf/Celecoxib%20prostate%20cancer.pdf","raw_type":"text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.1028.6360","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.1028.6360","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://hwmaint.jco.ascopubs.org/cgi/reprint/24/18/2723.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W1970400785","https://openalex.org/W1977078195","https://openalex.org/W1987152105","https://openalex.org/W2010397777","https://openalex.org/W2010973568","https://openalex.org/W2022282235","https://openalex.org/W2024087814","https://openalex.org/W2052964069","https://openalex.org/W2054279868","https://openalex.org/W2054429544","https://openalex.org/W2062813587","https://openalex.org/W2063113306","https://openalex.org/W2071879495","https://openalex.org/W2079766507","https://openalex.org/W2110430942","https://openalex.org/W2141283971","https://openalex.org/W2155679349","https://openalex.org/W2170271978","https://openalex.org/W4242442904","https://openalex.org/W4293168096"],"related_works":["https://openalex.org/W2109806675","https://openalex.org/W2079221337","https://openalex.org/W2054429544","https://openalex.org/W2281153014","https://openalex.org/W2993934172","https://openalex.org/W2791309531","https://openalex.org/W2132892424","https://openalex.org/W2025468362","https://openalex.org/W2077269737","https://openalex.org/W2601829345"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"assess":[2],"the":[3,28,112,126,144,154,181,189,197,230],"biologic":[4,210],"activity":[5,211],"of":[6,58,93,115,119,125,140,150,160,164,212,232],"celecoxib,":[7],"a":[8],"selective":[9],"cyclooxygenase-2":[10],"inhibitor,":[11],"in":[12,20,143,153,214],"men":[13,129,142,152,233],"with":[14,99,167,218],"recurrent":[15],"prostate":[16,39,215],"cancer":[17],"using":[18],"change":[19],"prostate-specific":[21],"antigen":[22],"(PSA)":[23],"doubling":[24],"time":[25],"(PSADT)":[26],"as":[27,90],"primary":[29,198],"outcome":[30,87],"variable.":[31],"PATIENTS":[32],"AND":[33],"METHODS:":[34],"Participants":[35],"had":[36,157],"histologically":[37],"confirmed":[38],"cancer,":[40],"no":[41,55,100,168],"recent":[42],"hormone":[43],"therapy,":[44,53],"rising":[45],"serum":[46],"PSA":[47,175,224],"after":[48,109],"radical":[49],"prostatectomy":[50],"and/or":[51],"radiation":[52],"and":[54,147,184,226],"radiographic":[56],"evidence":[57,208],"metastases.":[59,102],"Patients":[60],"were":[61,130],"randomly":[62,132],"assigned":[63,131],"to":[64,133,228],"celecoxib":[65,116,135,155,190,213,220],"(400":[66],"mg":[67],"by":[68,178,186],"mouth":[69],"twice":[70],"daily)":[71],"or":[72,79,136],"placebo.":[73,137],"Treatment":[74],"continued":[75],"until":[76,80],"disease":[77],"progression":[78],"adverse":[81],"effects":[82],"stopped":[83],"treatment.":[84],"A":[85],"positive":[86],"was":[88,106,201],"defined":[89],"post-treatment":[91,158],"PSADT":[92,98,159,166],"more":[94,161],"than":[95,162],"200%":[96,163],"baseline":[97,165],"new":[101,169],"RESULTS:":[103],"The":[104],"study":[105,205],"terminated":[107],"early":[108],"information":[110],"about":[111],"cardiovascular":[113],"safety":[114],"prompted":[117],"review":[118],"ongoing":[120],"clinical":[121],"studies.":[122],"Before":[123],"discontinuation":[124],"study,":[127],"78":[128],"either":[134],"Eight":[138],"(20%)":[139],"40":[141],"placebo":[145,182],"group":[146,156,183,191],"15":[148],"(40%)":[149],"38":[151],"metastases":[170],"(P":[171,192],"=":[172,193],".08).":[173],"Mean":[174],"velocity":[176,225],"increased":[177],"3.0%":[179],"for":[180,188,209],"decreased":[185,222],"3.4%":[187],".02).":[194],"CONCLUSION:":[195],"Although":[196],"efficacy":[199],"objective":[200],"not":[202],"met,":[203],"this":[204],"provides":[206],"some":[207],"cancer.":[216],"Compared":[217],"placebo,":[219],"significantly":[221],"mean":[223],"tended":[227],"increase":[229],"proportion":[231],"who":[234],"doubled":[235],"their":[236],"PSADT.":[237]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":13}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}